Developing novel ADC

immuno-therapeutics to

treat high need cancers

Lead program: Nectin-4-targeting ADC – with potential across a range of hard to treat cancers.

Innovative linker and payload technology to deliver higher efficacy, lower risk of side effects and ability to avoid tumor resistance.

Antibodies with unique properties designed to lower both on-target and off-target side effects.

About Us

Read More >


Read More >


Read More >


Read More >

Latest News


Emergence Therapeutics Announces Bumped-up Follow-on Seed Round Financing

Financing enables company to embark on additional targets and expand ADC technology reach Duisburg, Germany – Marseille, France, 25 November 2020: Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a syndicate of...

View Article >

Emergence Therapeutics AG Announces Establishment of Scientific Advisory Board

Key Opinion Leaders bring many years of ADC development expertise to the company Duisburg, Germany - Marseille, France, 10 March 2020: Emergence Therapeutics today announced that is has established its Scientific Advisory Board (SAB) to support the company in its goal to develop novel and innovative antibody-drug-conjugates (ADCs).

View Article >

Emergence Therapeutics AG Announces Key Hirings to Senior Management Team

Substantial experience in cancer targets, ADC technology as well as corporate finances and law Duisburg, Germany – Marseille, France, 22 January 2020: Emergence Therapeutics announced today that is has hired Florence Lhospice as Chief Development Officer and Carsten Dehning as Chief Financial Officer and member of the Executive Board to complement its management team. Dr....

View Article >